Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA

Oncogene

Volumn 30, Issue 11, 2011, Pages 1372-1378

  Marzec, M ^a   Liu, X ^a   Wong, W ^a,b   Yang, Y ^a   Pasha, T ^a   Kantekure, K ^a   Zhang, P ^a   Woetmann, A ^c   Cheng, M ^d   Odum, N ^c   Wasik, M A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d CEPHALON INC   (United States)

Author keywords

anaplastic lymphoma kinase; HIF1 ; oncogenic tyrosine kinase; STAT3

Indexed keywords

HYPOXIA INDUCED FACTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; NUCLEOPHOSMIN; PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; UPREGULATION; WILD TYPE;

ANOXIA; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOMA, T-CELL; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PHOSPHOTRANSFERASES; PROTEIN-TYROSINE KINASES; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 79952754066     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.505     Document Type: Article

References (29)

1. Bertout JA, Patel SA, Simon MC. (2008). The impact of O2 availability on human cancer. Nat Rev Cancer 8: 967-975.
2. Bischof D, Pulford K, Mason DY, Morris SW. (1997). Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17: 2312-2325. (Pubitemid 27133318)
3. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E et al. (2004). Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18: 2893-2904. (Pubitemid 39602308)
4. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J et al. (2003). NPM-ALK transgenic mice spontaneously develop T-cell lympho-mas and plasma cell tumors. Blood 101: 1919-1927. (Pubitemid 36237594)
5. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. (2008). The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8: 11-23.
6. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S et al. (1996). Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t (2; 5). Proc Natl Acad Sci USA 93: 4181-4186. (Pubitemid 26146730)
7. Evens AM, Schumacker PT, Helenowski IB, Singh AT, Dokic D, Keswani A et al. (2008). Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol 141: 676-680. (Pubitemid 351667626)
8. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L et al. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 104: 270-275. (Pubitemid 46068021)
9. Giatromanolaki A, Koukourakis MI, Pezzella F, Sivridis E, Turley H, Harris AL et al. (2008). Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 26: 219-224.
10. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. (2006). Nucleophosmin/ anaplastic lymphoma kinase (NPM/ALK) onco-protein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA 103: 9964-9969. (Pubitemid 43993606)
11. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY et al. (1997). Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90: 2901-2910. (Pubitemid 27444183)
12. Li R, Morris SW. (2008). Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28: 372-412. (Pubitemid 351590540)
13. Ling X, Arlinghaus RB. (2005). Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65: 2532-2536. (Pubitemid 40490046)
14. Lu L, Ghose AK, Quail MR, Albom MS, Durkin JT, Holskin BP et al. (2009). ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry 48: 3600-3609.
15. Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN et al. (2007). Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26: 5606-5614. (Pubitemid 47267838)
16. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N et al. (2005). Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 85: 1544-1554. (Pubitemid 41662338)
17. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M et al. (2008). Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-LI, B7-H1). Pro Natl Acad Sci USA 105: 20852-20857.
18. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284. (Pubitemid 24107549)
19. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X et al. (1997). ALK, the chromosome 2 gene locus altered by the t (2; 5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14: 2175-2188. (Pubitemid 27248229)
20. Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M et al. (2008). Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 6: 1099-1105.
21. Passam FH, Alexandrakis MG, Kafousi M, Fotinou M, Darivianaki K, Tsirakis G et al. (2009). Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 205: 11-20.
22. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732. (Pubitemid 37328811)
23. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. (1994). Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, S3. Oncogene 9: 1567-1574. (Pubitemid 24163381)
24. Wasik MA, Zhang Q, Marzec M, Kasprzycka M, Wang HY, Liu X. (2009). Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Semin Oncol 36: 27-35.
25. Wright CW, Duckett CS. (2009). The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-kappaB-dependent transcription. Science 323: 251-255.
26. Yu H, Jove R. (2004). The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105. (Pubitemid 38198738)
27. Yue P, Turkson J. (2009). Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18: 45-56.
28. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N et al. (2002). Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168: 466-474. (Pubitemid 34014150)
29. Zhang Q, Wang HY, Liu X, Wasik MA. (2007). STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med 13: 1341-1348. (Pubitemid 350073594)